Free Trial

Soligenix (SNGX) Competitors

Soligenix logo
$3.38 +0.02 (+0.45%)
As of 01:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SNGX vs. CLNN, MRSN, SCYX, RNXT, ALXO, OKUR, ESLA, CLSD, BTAI, and AKTX

Should you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Clene (CLNN), Mersana Therapeutics (MRSN), SCYNEXIS (SCYX), RenovoRx (RNXT), ALX Oncology (ALXO), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Clearside Biomedical (CLSD), BioXcel Therapeutics (BTAI), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry.

Soligenix vs. Its Competitors

Clene (NASDAQ:CLNN) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Soligenix has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat Soligenix's return on equity.

Company Net Margins Return on Equity Return on Assets
Clene-10,386.36% N/A -125.49%
Soligenix N/A -274.76%-129.20%

23.3% of Clene shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 35.3% of Clene shares are owned by insiders. Comparatively, 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Clene presently has a consensus target price of $33.00, suggesting a potential upside of 519.14%. Soligenix has a consensus target price of $6.00, suggesting a potential upside of 75.70%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than Soligenix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clene
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Soligenix
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Clene had 2 more articles in the media than Soligenix. MarketBeat recorded 12 mentions for Clene and 10 mentions for Soligenix. Soligenix's average media sentiment score of 0.10 beat Clene's score of -0.35 indicating that Soligenix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clene
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Soligenix
1 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Soligenix has lower revenue, but higher earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clene$340K156.61-$39.40M-$3.76-1.42
Soligenix$120K122.09-$8.27M-$3.80-0.90

Clene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.

Summary

Clene beats Soligenix on 12 of the 17 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNGX vs. The Competition

MetricSoligenixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$14.66M$3.11B$5.82B$9.73B
Dividend YieldN/A2.23%3.84%4.09%
P/E Ratio-0.9021.1130.9626.08
Price / Sales122.09394.05464.73119.69
Price / CashN/A43.0937.1558.38
Price / Book7.948.109.136.38
Net Income-$8.27M-$54.72M$3.26B$265.48M
7 Day Performance22.84%2.29%2.08%1.81%
1 Month Performance142.20%7.21%5.01%1.12%
1 Year Performance-19.46%12.64%31.22%21.02%

Soligenix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNGX
Soligenix
2.1337 of 5 stars
$3.38
+0.4%
$6.00
+77.8%
-24.7%$14.48M$120K-0.8920Gap Down
CLNN
Clene
3.2071 of 5 stars
$4.24
+17.1%
$33.00
+678.3%
+3.5%$36.17M$340K-1.13100Analyst Forecast
High Trading Volume
MRSN
Mersana Therapeutics
4.1992 of 5 stars
$7.38
+3.1%
$56.60
+666.9%
-76.7%$35.73M$34.77M-0.50150
SCYX
SCYNEXIS
1.0624 of 5 stars
$0.80
-4.5%
N/A-54.3%$35.21M$3.75M-2.0160News Coverage
Analyst Revision
RNXT
RenovoRx
2.9115 of 5 stars
$0.94
-1.6%
$7.25
+671.3%
-15.7%$34.94M$40K-2.476News Coverage
Short Interest ↓
Analyst Revision
ALXO
ALX Oncology
2.5501 of 5 stars
$0.97
+50.7%
$3.30
+239.9%
-58.8%$34.50MN/A-0.4440Analyst Revision
Gap Down
High Trading Volume
OKUR
OnKure Therapeutics
3.1862 of 5 stars
$2.80
+10.7%
$32.33
+1,054.8%
N/A$34.18MN/A-0.58N/A
ESLA
Estrella Immunopharma
2.8359 of 5 stars
$0.92
+1.0%
$16.00
+1,640.1%
-37.6%$33.73MN/A-3.54N/A
CLSD
Clearside Biomedical
2.2284 of 5 stars
$0.43
+0.7%
$4.20
+886.1%
-60.1%$33.21M$4.17M-1.1530Negative News
BTAI
BioXcel Therapeutics
4.5765 of 5 stars
$5.67
+3.5%
$39.75
+601.1%
-52.0%$33.19M$2.27M-0.4590Short Interest ↓
AKTX
Akari Therapeutics
2.3884 of 5 stars
$1.00
-1.0%
$5.00
+400.0%
-74.2%$32.50MN/A0.009

Related Companies and Tools


This page (NASDAQ:SNGX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners